Work

The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.7_suppl.183

Authors: Andrew J. Armstrong, Mohammed Al-Adhami, Ping Lin, Teresa Parli, Jennifer Sugg, Joyce Leta Steinberg, Bertrand F. TOMBAL, Cora N. Sternberg, Johann S. De Bono, Howard I. Scher, Tomasz M. Beer

Institutions: Duke University, Duke Cancer Institute, Pfizer (United States), Astellas Pharma (United States), Cliniques Universitaires Saint-Luc, Weill Cornell Medicine, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, OHSU Knight Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2920797229

Cites:

Cited by:

Related to: 10